JP2010524937A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010524937A5 JP2010524937A5 JP2010504069A JP2010504069A JP2010524937A5 JP 2010524937 A5 JP2010524937 A5 JP 2010524937A5 JP 2010504069 A JP2010504069 A JP 2010504069A JP 2010504069 A JP2010504069 A JP 2010504069A JP 2010524937 A5 JP2010524937 A5 JP 2010524937A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- methyl
- composition
- pharmaceutically acceptable
- triazol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 12
- 239000000203 mixture Substances 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 11
- 239000011780 sodium chloride Substances 0.000 claims 11
- 239000012453 solvate Substances 0.000 claims 11
- 201000011510 cancer Diseases 0.000 claims 7
- 125000001153 fluoro group Chemical group F* 0.000 claims 4
- 229910052731 fluorine Inorganic materials 0.000 claims 3
- NJIFUSHVKTYKOQ-UHFFFAOYSA-N 2-(1,1-difluoroethyl)-5-[1-[4-methyl-5-[2-(trifluoromethyl)phenyl]-1,2,4-triazol-3-yl]-4-bicyclo[2.2.2]octanyl]-1,3,4-oxadiazole Chemical compound CN1C(C=2C(=CC=CC=2)C(F)(F)F)=NN=C1C(CC1)(CC2)CCC12C1=NN=C(C(C)(F)F)O1 NJIFUSHVKTYKOQ-UHFFFAOYSA-N 0.000 claims 2
- AHAIJYTWSYJSSZ-UHFFFAOYSA-N 5-(1,1-difluoroethyl)-3-[4-[4-methyl-5-[2-(trifluoromethyl)phenyl]-1,2,4-triazol-3-yl]-1-bicyclo[2.2.2]octanyl]-1,2,4-oxadiazole Chemical compound CN1C(C=2C(=CC=CC=2)C(F)(F)F)=NN=C1C(CC1)(CC2)CCC12C1=NOC(C(C)(F)F)=N1 AHAIJYTWSYJSSZ-UHFFFAOYSA-N 0.000 claims 2
- XUUUVCWUOYEAQD-UHFFFAOYSA-N 5-(2-fluoropropan-2-yl)-3-[4-[4-methyl-5-[2-(trifluoromethyl)phenyl]-1,2,4-triazol-3-yl]-1-bicyclo[2.2.2]octanyl]-1,2,4-oxadiazole Chemical compound CN1C(C=2C(=CC=CC=2)C(F)(F)F)=NN=C1C(CC1)(CC2)CCC12C1=NOC(C(C)(C)F)=N1 XUUUVCWUOYEAQD-UHFFFAOYSA-N 0.000 claims 2
- HKJOIWLYDJCTQR-UHFFFAOYSA-N 5-(3,3-difluorocyclobutyl)-3-[4-[4-methyl-5-[2-(trifluoromethyl)phenyl]-1,2,4-triazol-3-yl]-1-bicyclo[2.2.2]octanyl]-1,2,4-oxadiazole Chemical compound CN1C(C=2C(=CC=CC=2)C(F)(F)F)=NN=C1C(CC1)(CC2)CCC12C(N=1)=NOC=1C1CC(F)(F)C1 HKJOIWLYDJCTQR-UHFFFAOYSA-N 0.000 claims 2
- 206010004146 Basal cell carcinoma Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000000172 Medulloblastoma Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000587 Small Cell Lung Carcinoma Diseases 0.000 claims 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims 2
- 230000001668 ameliorated Effects 0.000 claims 2
- 230000003042 antagnostic Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000002496 gastric Effects 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- XRMWTBNQSOBMMT-UHFFFAOYSA-N 2-(2-fluoropropan-2-yl)-5-[1-[4-methyl-5-[2-(trifluoromethyl)phenyl]-1,2,4-triazol-3-yl]-4-bicyclo[2.2.2]octanyl]-1,3,4-oxadiazole Chemical compound CN1C(C=2C(=CC=CC=2)C(F)(F)F)=NN=C1C(CC1)(CC2)CCC12C1=NN=C(C(C)(C)F)O1 XRMWTBNQSOBMMT-UHFFFAOYSA-N 0.000 claims 1
- WTAGZHGHXQGOQC-UHFFFAOYSA-N 2-(3,3-difluorocyclobutyl)-5-[1-[4-methyl-5-[2-(trifluoromethyl)phenyl]-1,2,4-triazol-3-yl]-4-bicyclo[2.2.2]octanyl]-1,3,4-oxadiazole Chemical compound CN1C(C=2C(=CC=CC=2)C(F)(F)F)=NN=C1C(CC1)(CC2)CCC12C(O1)=NN=C1C1CC(F)(F)C1 WTAGZHGHXQGOQC-UHFFFAOYSA-N 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000007276 Esophageal Squamous Cell Carcinoma Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 206010024324 Leukaemias Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010027191 Meningioma Diseases 0.000 claims 1
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 claims 1
- 108009000071 Non-small cell lung cancer Proteins 0.000 claims 1
- 206010061534 Oesophageal squamous cell carcinoma Diseases 0.000 claims 1
- 206010025310 Other lymphomas Diseases 0.000 claims 1
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 125000004429 atoms Chemical group 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000009251 multiple myeloma Diseases 0.000 claims 1
- 125000004433 nitrogen atoms Chemical group N* 0.000 claims 1
- 125000004430 oxygen atoms Chemical group O* 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000002534 radiation-sensitizing agent Substances 0.000 claims 1
- 231100000489 sensitizer Toxicity 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
Claims (15)
- X及びYの一方がOであり、もう一方が、Nであり、Zが、Nである、請求項1に記載の組成物。
- 該化合物が、
5−(1,1−ジフルオロエチル)−3−(4−{4−メチル−5−[2−(トリフルオロメチル)フェニル]−4H−1,2,4−トリアゾール−3−イル}ビシクロ[2.2.2]オクタ−1−イル)−1,2,4−オキサジアゾール;
5−(3,3−ジフルオロシクロブチル)−3−(4−{4−メチル−5−[2−(トリフルオロメチル)フェニル]−4H−1,2,4−トリアゾール−3−イル}ビシクロ[2.2.2]オクタ−1−イル)−1,2,4−オキサジアゾール;
5−(1−フルオロ−1−メチルエチル)−3−(4−{4−メチル−5−[2−(トリフルオロメチル)フェニル]−4H−1,2,4−トリアゾール−3−イル}ビシクロ[2.2.2]オクタ−1−イル)−1,2,4−オキサジアゾール;
2−(1,1−ジフルオロエチル)−5−(4−{4−メチル−5−[2−(トリフルオロメチル)フェニル]−4H−1,2,4−トリアゾール−3−イル}ビシクロ[2.2.2]オクタ−1−イル)−1,3,4−オキサジアゾール;
2−(3,3−ジフルオロシクロブチル)−5−(4−{4−メチル−5−[2−(トリフルオロメチル)フェニル]−4H−1,2,4−トリアゾール−3−イル}ビシクロ[2.2.2]オクタ−1−イル)−1,3,4−オキサジアゾール
2−(1−フルオロ−1−メチルエチル)−5−(4−{4−メチル−5−[2−(トリフルオロメチル)フェニル]−4H−1,2,4−トリアゾール−3−イル}ビシクロ[2.2.2]オクタ−1−イル)−1,3,4−オキサジアゾール;
又はその薬学的に許容される塩若しくは溶媒和物から選択される、請求項1に記載の組成物。 - 該化合物が、
5−(1,1−ジフルオロエチル)−3−(4−{4−メチル−5−[2−(トリフルオロメチル)フェニル]−4H−1,2,4−トリアゾール−3−イル}ビシクロ[2.2.2]オクタ−1−イル)−1,2,4−オキサジアゾール;
又はその薬学的に許容される塩若しくは溶媒和物である、請求項1に記載の組成物。 - 該化合物が:
5−(3,3−ジフルオロシクロブチル)−3−(4−{4−メチル−5−[2−(トリフルオロメチル)フェニル]−4H−1,2,4−トリアゾール−3−イル}ビシクロ[2.2.2]オクタ−1−イル)−1,2,4−オキサジアゾール;
又はその薬学的に許容される塩若しくは溶媒和物である、請求項1に記載の組成物。 - 該化合物が:
5−(1−フルオロ−1−メチルエチル)−3−(4−{4−メチル−5−[2−(トリフルオロメチル)フェニル]−4H−1,2,4−トリアゾール−3−イル}ビシクロ[2.2.2]オクタ−1−イル)−1,2,4−オキサジアゾール;
又はその薬学的に許容される塩若しくは溶媒和物である、請求項1に記載の組成物。 - 該化合物が:
2−(1,1−ジフルオロエチル)−5−(4−{4−メチル−5−[2−(トリフルオロメチル)フェニル]−4H−1,2,4−トリアゾール−3−イル}ビシクロ[2.2.2]オクタ−1−イル)−1,3,4−オキサジアゾール;
又はその薬学的に許容される塩若しくは溶媒和物である、請求項1に記載の組成物。 - 該状態が癌である、請求項1ないし8のいずれか一項に記載の組成物。
- 該癌が、基底細胞癌、髄芽腫、前立腺癌、膵臓癌、乳癌、結腸癌、小細胞肺癌、肉腫、リンパ腫、白血病、消化管癌、多発性骨髄腫、神経膠腫、ヘプタセルラー、非小細胞肺癌、弧発性及び家族性基底細胞癌、弧発性髄芽腫、髄膜腫、乳癌、食道扁平上皮癌、及び膀胱癌から選択される、請求項9に記載の組成物。
- 請求項1から8のいずれか一項に記載の化合物又はその薬学的に許容される塩若しくは溶媒和物の、癌治療のための医薬を製造するための化学増感剤及び放射線増感剤としての使用。
- 癌の治療又は予防において使用するための、請求項1から8のいずれか一項に記載の化合物又はその薬学的に許容される塩若しくは溶媒和物。
- 同時投与、別個の投与、又は逐次投与のための、請求項1から8のいずれか一項に記載の化合物又はその薬学的に許容される塩若しくは溶媒和物、及び抗癌剤。
- Smo拮抗作用によって改善され得る状態を治療又は予防するための医薬の製造のための、請求項1から8のいずれか一項に記載の化合物又はその薬学的に許容される塩若しくは溶媒和物の使用。
- 該癌が、前立腺癌、非小細胞肺癌、消化管癌、及び膀胱癌から選択される、請求項10に記載の組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US92501807P | 2007-04-18 | 2007-04-18 | |
US60/925,018 | 2007-04-18 | ||
PCT/US2008/004862 WO2008130552A1 (en) | 2007-04-18 | 2008-04-15 | Triazole derivatives which are smo antagonists |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2010524937A JP2010524937A (ja) | 2010-07-22 |
JP2010524937A5 true JP2010524937A5 (ja) | 2011-05-19 |
JP5498936B2 JP5498936B2 (ja) | 2014-05-21 |
Family
ID=39433852
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010504069A Active JP5498936B2 (ja) | 2007-04-18 | 2008-04-15 | Smoアンタゴニストであるトリアゾール誘導体 |
Country Status (12)
Country | Link |
---|---|
US (1) | US7691887B2 (ja) |
EP (1) | EP2136803B1 (ja) |
JP (1) | JP5498936B2 (ja) |
CN (1) | CN101663033B (ja) |
AR (1) | AR066063A1 (ja) |
AT (1) | ATE555785T1 (ja) |
AU (1) | AU2008241527B2 (ja) |
CA (1) | CA2683946C (ja) |
CL (1) | CL2008001074A1 (ja) |
PE (1) | PE20090806A1 (ja) |
TW (1) | TW200901987A (ja) |
WO (1) | WO2008130552A1 (ja) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI433674B (zh) | 2006-12-28 | 2014-04-11 | Infinity Discovery Inc | 環杷明(cyclopamine)類似物類 |
US8716479B2 (en) | 2007-12-27 | 2014-05-06 | Infinity Pharmaceuticals, Inc. | Methods for stereoselective reduction |
US20100297118A1 (en) * | 2007-12-27 | 2010-11-25 | Macdougall John | Therapeutic Cancer Treatments |
AR070047A1 (es) * | 2007-12-27 | 2010-03-10 | Infinity Pharmaceuticals Inc | Tratamientos terapeuticos contra el cancer. composicion que comprende un inhibidor de hedgehog. |
GB0813740D0 (en) * | 2008-07-28 | 2008-09-03 | Angeletti P Ist Richerche Biologica | Therapeutic compounds |
JP5816087B2 (ja) * | 2008-08-29 | 2015-11-18 | エンメエッセディ・イタリア・エッセ・エッレ・エッレ | Smoアンタゴニストとしての飽和二環式複素環誘導体 |
CN102574791A (zh) | 2009-08-05 | 2012-07-11 | 无限药品股份有限公司 | 环杷明类似物的酶促转氨基反应 |
CA2781300A1 (en) * | 2009-11-20 | 2011-05-26 | Infinity Pharmaceuticals, Inc. | Methods and compositions for treating hedgehog-associated cancers |
WO2012037217A1 (en) | 2010-09-14 | 2012-03-22 | Infinity Pharmaceuticals, Inc. | Transfer hydrogenation of cyclopamine analogs |
KR20160061911A (ko) | 2013-04-08 | 2016-06-01 | 데니스 엠. 브라운 | 최적하 투여된 화학 화합물의 치료 효과 |
CN104324039A (zh) * | 2014-10-20 | 2015-02-04 | 付茜 | 一种治疗人身体表面脂肪瘤的药剂及使用方法 |
AU2016271468B2 (en) | 2015-06-04 | 2020-01-02 | Sol-Gel Technologies Ltd. | Topical formulations for delivery of hedgehog inhibitor compounds and use thereof |
CN108623446A (zh) * | 2017-03-24 | 2018-10-09 | 北京艾德旺科技发展有限公司 | 一种合成3,3-二氟环丁烷甲酸的方法 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7291626B1 (en) * | 1998-04-09 | 2007-11-06 | John Hopkins University School Of Medicine | Inhibitors of hedgehog signaling pathways, compositions and uses related thereto |
AU2003207717B9 (en) | 2002-02-01 | 2009-05-07 | Merck & Co., Inc. | 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia |
JO2397B1 (en) * | 2002-12-20 | 2007-06-17 | ميرك شارب اند دوم كوربوريشن | Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors |
WO2004106294A2 (en) | 2003-05-29 | 2004-12-09 | Merck & Co., Inc. | Triazole derivatives as inhibitors of 11-beta hydroxysteroid dehydrogenase-1 |
US8067608B2 (en) | 2003-09-29 | 2011-11-29 | The Johns Hopkins University | Hedgehog pathway antagonists |
CA2565237C (en) | 2004-04-30 | 2012-12-11 | Genentech, Inc. | Quinoxaline inhibitors of hedgehog signalling |
CA2575736A1 (en) | 2004-08-06 | 2006-02-16 | Merck & Co., Inc. | Sulfonyl compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1 |
AU2005280112B2 (en) | 2004-08-27 | 2012-07-19 | Infinity Pharmaceuticals, Inc. | Cyclopamine analogues and methods of use thereof |
EA017262B1 (ru) | 2004-09-02 | 2012-11-30 | Дженентек, Инк. | Соединения 2-(2-галоген-4-аминофенил)пиридиновых ингибиторов передачи сигналов белком hedgehog (варианты), способ их получения, композиция и способы лечения рака и ингибирований ангиогенеза и сигнального пути hedgehog в клетках на их основе |
RU2007119637A (ru) | 2004-10-28 | 2008-12-10 | Айрм Ллк (Bm) | Соединения и композиции в качестве модуляторов hedgehog-пути |
EP1807074B1 (en) | 2004-11-03 | 2013-10-23 | Curis, Inc. | Mediators of hedgehog signaling pathways, compositions and uses related thereto |
CN103724335A (zh) * | 2005-10-20 | 2014-04-16 | 默沙东公司 | 用作11β-羟基类固醇脱氢酶-1抑制剂的三唑衍生物 |
-
2008
- 2008-04-15 WO PCT/US2008/004862 patent/WO2008130552A1/en active Application Filing
- 2008-04-15 JP JP2010504069A patent/JP5498936B2/ja active Active
- 2008-04-15 CN CN2008800127274A patent/CN101663033B/zh active Active
- 2008-04-15 CL CL2008001074A patent/CL2008001074A1/es unknown
- 2008-04-15 CA CA2683946A patent/CA2683946C/en active Active
- 2008-04-15 TW TW097113665A patent/TW200901987A/zh unknown
- 2008-04-15 PE PE2008000654A patent/PE20090806A1/es not_active Application Discontinuation
- 2008-04-15 EP EP08742913A patent/EP2136803B1/en active Active
- 2008-04-15 US US12/082,933 patent/US7691887B2/en active Active
- 2008-04-15 AR ARP080101540A patent/AR066063A1/es unknown
- 2008-04-15 AU AU2008241527A patent/AU2008241527B2/en active Active
- 2008-04-15 AT AT08742913T patent/ATE555785T1/de active
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2010524937A5 (ja) | ||
JP2008516982A5 (ja) | ||
US20160120849A1 (en) | Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor | |
JP2011502958A5 (ja) | ||
JP2017505762A5 (ja) | ||
US20130156755A1 (en) | Cancer therapy using a combination of a hsp90 inhibitory compounds and a vegf inhibitor | |
JP2009538897A5 (ja) | ||
JP2013516393A5 (ja) | ||
JP2008535902A5 (ja) | ||
JP2011507849A5 (ja) | ||
JP2014533299A5 (ja) | ||
JP2015531366A5 (ja) | ||
JP2014526500A5 (ja) | ||
JP2011500806A5 (ja) | ||
JP2010515715A5 (ja) | ||
JP2011517457A5 (ja) | ||
JP2013537229A5 (ja) | ||
JP2011504903A5 (ja) | ||
JP2008526723A5 (ja) | ||
JP2010526814A5 (ja) | ||
RU2008140940A (ru) | Производное триазола или его соль | |
JP2009526034A5 (ja) | ||
JP2009536196A5 (ja) | ||
JP2005517006A5 (ja) | ||
JP2014507443A5 (ja) |